

Abstract of the Disclosure

The present invention is directed to methods and devices for delivering an active
5 agent formulation to the lung of a human patient. The active agent formulation may be in
dry powder form, it may be nebulized, or it may be in admixture with a propellant. The
active agent formulation is delivered to a patient at a low inspiratory flow rate for an
initial period of time to increase bioavailability of the active agent.